Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Abstract

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has not been evaluated. We conducted a multicenter phase I trial combining healthy donor FMT with the PD-1 inhibitors nivolumab or pembrolizumab in 20 previously untreated patients with advanced melanoma. The primary end point was safety. No grade 3 adverse events were reported from FMT alone. Five patients (25%) experienced grade 3 immune-related adverse events from combination therapy. Key secondary end points were objective response rate, changes in gut microbiome composition and systemic immune and metabolomics analyses. The objective response rate was 65% (13 of 20), including four (20%) complete responses. Longitudinal microbiome profiling revealed that all patients engrafted strains from their respective donors; however, the acquired similarity between donor and patient microbiomes only increased over time in responders. Responders experienced an enrichment of immunogenic and a loss of deleterious bacteria following FMT. Avatar mouse models confirmed the role of healthy donor feces in increasing anti-PD-1 efficacy. Our results show that FMT from healthy donors is safe in the first-line setting and warrants further investigation in combination with immune checkpoint inhibitors. ClinicalTrials.gov identifier NCT03772899 .

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02453-x

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

13 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 76 references

Cited by

See all 554

Metadata

Authors
Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., Ernst, S., Logan, D., Belanger, K., Esfahani, K., Richard, C., Ninkov, M., Piccinno, G., Armanini, F., Pinto, F., Krishnamoorthy, M., Figueredo, R., Thebault, P., Takis, P., Magrill, J., Ramsay, L., Derosa, L., Marchesi, J. R., Parvathy, S. N., Elkrief, A., Watson, I. R., Lapointe, R., Segata, N., Haeryfar, S. M. M., Mullish, B. H., Silverman, M. S., Burton, J. P., & Maleki Vareki, S.
Affiliations
  • Centre Hospitalier de l’Université de Montréal (CA)
  • Western University (CA)
  • Jewish General Hospital (CA)
  • University of Trento (IT)
  • Imperial College London (GB)
  • Institut du cancer Rosalind & Morris Goodman (CA)
  • Inserm (FR)
  • St Mary's Hospital (GB)
  • Imperial College Healthcare NHS Trust (GB)
Venue
Nature Medicine
Published
2023-07-06
Volume
29
Issue
8
Pages
2121-2132
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4383341159
Cited by
526
References
76
Citations by year
2026: 174 · 2025: 197 · 2024: 132 · 2023: 22
FWCI
64.04
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
Funders
  • Lotte and John Hecht Memorial Foundation
  • Canadian Institute of Health Research
  • Canadian Cancer Society Impact Grant
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
fecal microbiota transplantation, anti-PD-1 therapy, advanced melanoma, nivolumab, pembrolizumab, immune checkpoint inhibitors, first-line therapy, gut microbiota, immune-related adverse events, donor engraftment
MeSH terms
Fecal Microbiota Transplantation, Immune Checkpoint Inhibitors, Animals, Feces, Humans, Immunotherapy, Melanoma, Treatment Outcome, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. https://app.cochat.ai/papers/10.1038/s41591-023-02453-x
The paper
Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., Ernst, S., Logan, D., Belanger, K., Esfahani, K., Richard, C., Ninkov, M., Piccinno, G., Armanini, F., Pinto, F., . . . Maleki Vareki, S. (2023). Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02453-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.